Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.46 |
| ▸ | XIAP | P98170 | 2/20 | 0.44 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566972 | 0.94 | XIAP (0.45) | ELANEXIAPMLXCMA1TAAR1 | |
| SCHEMBL13567377 | 0.94 | XIAP (0.44) | ELANEXIAPMLXCMA1TAAR1 | |
| SCHEMBL29567397 | 0.94 | ELANE (0.50) | ELANEXIAPMLXCMA1TAAR1 | |
| SCHEMBL29567377 | 0.93 | XIAP (0.47) | ELANEXIAPMLXCMA1ACE | |
| SCHEMBL11989026 | 0.93 | ELANE (0.44) | ELANEXIAPMLXTAAR1CALCRL | |
| SCHEMBL30620966 | 0.93 | XIAP (0.45) | ELANEXIAPMLXCMA1TAAR1 | |
| SCHEMBL29567754 | 0.93 | ELANE (0.48) | ELANEXIAPMLXCMA1TAAR1 | |
| SCHEMBL1506410 | 0.91 | ELANE (0.45) | ELANEXIAPMLXCMA1CALCRL | |
| SCHEMBL1506412 | 0.91 | ELANE (0.45) | ELANEXIAPMLXCMA1CALCRL | |
| SCHEMBL29567365 | 0.90 | NTSR1 (0.40) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332221-A1 | METHODS AND COMPOSITIONS FOR TREATING MUSCLE DISEASE AND DISORDERS | IMMUNOFORGE CO LTD (KR) | 2025-10-30 | — | — | US | disclosed |
| US-20250325635-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | IMMUNOFORGE CO LTD (KR) | 2025-10-23 | — | — | US | disclosed |
| US-20250276072-A1 | ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE | Immunoforge Co., Ltd. (KR) | 2025-09-04 | — | — | US | disclosed |
| US-12201643-B2 | Mechanochemical dynamic for focal cancer treatment | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240294608-A1 | ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE | Immunoforge Co., Ltd. (KR) | 2024-09-05 | — | — | US | disclosed |
| CN-118078955-A | ELP fusion proteins for controlled and sustained release | 免疫新炉有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118078956-A | ELP fusion proteins for controlled and sustained release | 免疫新炉有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240091313-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | Immunoforge Co., Ltd. (KR) | 2024-03-21 | — | — | US | disclosed |
| US-20230414773-A1 | ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE | PHASEBIO PHARMACEUTICALS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4295858-A1 | FORMULATIONS OF ACTIVE AGENTS FOR SUSTAINED RELEASE | ImmunoForge Co., Ltd. (KR) | 2023-12-27 | — | — | EP | disclosed |
| US-20230119684-A1 | MECHANOCHEMICAL DYNAMIC FOR FOCAL CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230000952-A1 | THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES | DUKE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| EP-4074327-A1 | THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES | Duke University (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20220288170-A1 | METHODS AND COMPOSITIONS FOR TREATING MUSCLE DISEASE AND DISORDERS | Immunoforge Co., Ltd. (KR) | 2022-09-15 | — | — | US | disclosed |
| US-20220289812-A1 | ELP FUSION PROTEINS COMPRISING PARATHYROID HORMONE FOR CONTROLLED AND SUSTAINED RELEASE | Immunoforge Co., Ltd. (KR) | 2022-09-15 | — | — | US | disclosed |
| EP-4043010-A1 | ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE | Phasebio Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114652817-A | Methods and compositions for treating muscle diseases and disorders | 费斯生物制药公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-4010008-A1 | ELP FUSION PROTEINS COMPRISING PARATHYROID HORMONE FOR CONTROLLED AND SUSTAINED RELEASE | Phasebio Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11266719-B2 | Methods and compositions for treating muscle disease and disorders | PHASEBIO PHARMACEUTICALS, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| CN-107427556-B | Methods and compositions for treating muscle diseases and disorders | 费斯生物制药公司 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091313-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | VIP, VIPR1, VIPR2 | ELANE 1494/4885XIAP 937/4885MLX 2070/4885 |
| US-20250325635-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | VIP, VIPR1, VIPR2 | ELANE 1494/4885XIAP 937/4885MLX 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.